Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 12/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517111 | 1.00 | FKBP1A (0.47) | FKBP1AHSD17B10SMN1; SMN2ROCK2HPGD | |
| SCHEMBL4154856 | 1.00 | FKBP1A (0.47) | FKBP1AHSD17B10SMN1; SMN2ROCK2HPGD | |
| SCHEMBL750515 | 0.95 | HSD17B10 (0.50) | FKBP1AHSD17B10SMN1; SMN2ROCK2LMNA | |
| SCHEMBL11932167 | 0.95 | HSD17B10 (0.50) | FKBP1AHSD17B10SMN1; SMN2ROCK2LMNA | |
| SCHEMBL27410636 | 0.89 | HSD17B10 (0.52) | FKBP1AHSD17B10SMN1; SMN2ROCK2LMNA | |
| SCHEMBL6234399 | 0.88 | HSD17B10 (0.39) | FKBP1AHSD17B10SMN1; SMN2ROCK2HPGD | |
| SCHEMBL927348 | 0.87 | HSD17B10 (0.56) | FKBP1AHSD17B10SMN1; SMN2HPGDLMNA | |
| SCHEMBL28153746 | 0.87 | HSD17B10 (0.56) | FKBP1AHSD17B10SMN1; SMN2HPGDLMNA | |
| SCHEMBL12529807 | 0.87 | FKBP1A (0.47) | FKBP1AHSD17B10ROCK2HPGDCASP3 | |
| SCHEMBL3880061 | 0.85 | FKBP1A (0.46) | FKBP1AHSD17B10ROCK2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114736201-A | Preparation method of umeclidinium bromide intermediate | 奥锐特药业(天津)有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-9771375-B2 | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-26 | — | — | US | disclosed |
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | VTV THERAPEUTICS LLC | 2015-05-28 | — | — | US | disclosed |
| EP-2560962-B1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-8987295-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140336170-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-11-13 | — | — | US | disclosed |
| US-8822447-B2 | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-02 | — | — | US | disclosed |
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009010480-A1 | 1-{2-[(DIPHENYL)AMINO]-ETHYL}-PIPERIDINE-4-CARBOXYLIC ACID BENZYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CCR5 AGONISTS FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
| EP-1960347-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | Sterix Limited (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008061016-A1 | N-SUBSTITUTED PIPERIDINYL 4 -ARYLSULFONAMIDES AS MODULATORS OF THE SECRETED FRIZZLED RELATED PROTEIN- 1 | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
| CN-101094840-A | Quinazoline derivatives for inhibiting the growth of cancer cells and methods for preparing the same | HANMI PHARM IND CO LTD (KR) | 2007-12-26 | — | — | CN | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| EP-1831194-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007003934-A2 | 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS | STERIX LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006068594-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLP1R, GIPR, GPR119 | FKBP1A 2108/4885HSD17B10 1129/4885SMN1; SMN2 3375/4885 |
| US-20140336170-A1 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS | KHK, GCK, GCKR | FKBP1A 2147/4885HSD17B10 279/4885SMN1; SMN2 4799/4885 |
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | FKBP1A 2549/4885HSD17B10 4616/4885SMN1; SMN2 3088/4885 |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | GLP1R, GIPR, GPR119 | FKBP1A 1681/4885HSD17B10 784/4885SMN1; SMN2 4000/4885 |
| US-20070254872-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | FKBP1A 3162/4885HSD17B10 3178/4885SMN1; SMN2 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.